About Celgosivir (MX-3253)
Celgosivir, an oral inhibitor of alpha-glucosidase I, is currently the only anti-HCV drug in clinical development that acts on host-directed glycosylation. In preclinical studies, celgosivir has shown excellent in vitro synergy with various interferons in the clinic or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in development for the treatment of HCV (e.g. polymerase inhibitors) and therefore has the potential to be included as part of many combination therapeutic approaches to improve efficacy in anti-HCV therapy.
A previously completed Phase II non-responder combination study
reported April 11, 2007 showed:
- a 42% Early Virologic Response(x) (EVR) with PRC compared to a 10%
EVR with PR ((x) EVR = 2 log(10) or greater HCV viral load
reduction at 12 weeks).
- a mean HCV viral load reduction ("VLR") of 1.63 log(10) (PRC)
compared to a 0.92 log(10) reduction (PR).
- 90% viral load reduction (1 log(10)) reduction, or greater, at
12 weeks in 66% (8/12) of PRC patients, compared to only 40% (4/10)
in patients in the PR treatment arm.
- EVR in 57% of null responders (4/7) in the PRC therapy arm (null
responders = patients who have not achieved greater than a
0.4 log(10) viral load reduction on prior treatment with optimized
Celgosivir combination therapy was well tolerated and resulted in no
|SOURCE MIGENIX Inc.|
Copyright©2007 PR Newswire.
All rights reserved